Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
China's Deputy Health Minister Yin Li on Tuesday said that public health cooperation between China and the U.S. can improve the health of both countries and be strategically significant to world peace and development, Xinhua/China View reports (7/29).
Health officials are growing increasingly concerned over the impact the H1N1 (swine) flu is having on populations living in Latin America, a region "which accounts for around two-thirds of the 816 confirmed deaths so far from the disease," the AFP/channelnewsasia.com reports. "The outlook is especially unsettling for the estimated 380 million people grappling with winter in South America, where the A(H1N1) virus is speedily propagating," the news service writes.
With hospitals around Australia struggling to cope with the added burden of swine flu cases researchers say 1 in 6 health workers will not report in for work in a flu pandemic.
The child vaccine is similar to the adult one and two types of dose strengths and amounts will be tested in order to determine the correct dosage and the safety of the vaccine - it will be tested on children aged between six months and eight years in Melbourne, Adelaide, Perth, Sydney and Brisbane.
The WHO on Friday said the "H1N1 swine-flu virus could infect up to two billion people over the next two years - about one of every three people in the world," VOA News reports.
Scientists in New Zealand who have been examining the spread of the new H1N1 flu (swine flu), say the virus appears more infectious than previously thought and a person who becomes ill with the new strain will on average infect almost two others.
"Global health officials are scrambling to try to prevent the spread of the H1N1 swine flu virus, with U.S. officials moving Thursday with a recommendation that the Food and Drug Administration (FDA) approve or license a [new H1N1] vaccine," without waiting on the results from "clinical trials to test its safety and efficacy," Wall Street Journal reports (Dooren/Winning, 7/24).
The U.S. Food and Drug Administration today announced it has issued an Emergency Use Authorization (EUA) for a another diagnostic test for the 2009 H1N1 influenza virus, whose spread has caused the virus to be characterized as a pandemic by the World Health Organization.
Experts in intensive care and anaesthesia have predicted that the current swine flu pandemic could overwhelm critical care beds and ventilators in England, with hospitals on the South East Coast, and in the South West, East of England and East Midlands, being worst hit.
A leading microbiologist from the University of Southampton has told a conference that his research has found copper is effective in inhibiting the influenza A H1N1 virus.
Brits will soon have direct access to a pandemic flu service which will make drugs for swine flu available without needing to consult a doctor.
The worldwide death toll from the H1N1 (swine flu) virus has doubled in the past month, reaching over 700, the WHO announced Tuesday, the AP/Google.com reports.
As Australian scientists embark on the first trials of a swine flu vaccine the World Health Organisation (WHO) has announced that the H1N1 virus (swine flu) has now killed more than 700 people around the world since the outbreak began four months ago.
Scientists in a network of medical research institutions across the United States are set to begin a series of clinical trials to gather critical data about influenza vaccines, including two candidate H1N1 flu vaccines. The research will be under the direction of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
A new interactive website providing accurate, bang-up-to-date information on swine flu to the general public launches today.
The U.S. Food and Drug Administration today announced that it has approved a vaccine for 2009-2010 seasonal influenza in the United States.
According to the World Health Organization (WHO) the H1N1 influenza A pandemic (swine flu) has killed around a total of 430 people and as health officials worldwide grapple to deal with rapid rise in the number of cases, airlines in Britain are blocking travellers suspected of having swine flu.
The Australian government is planning to spend $44 million over a four year period on extra vaccinations for seasonal flu - this will provide enough vaccinations for another 2.2 million people which will be available from January 1st next year.
A protein in influenza virus that helps it multiply also damages lung epithelial cells, causing fluid buildup in the lungs, according to new research from the University of Alabama at Birmingham (UAB) and Southern Research Institute . Publishing online this week in the journal of the Federation of American Societies for Experimental Biology, the researchers say the findings give new insight into how flu attacks the lungs and provides targets for new treatments.
As part of a series about Americans' response to the H1N1 flu outbreak, the Harvard Opinion Research Program at the Harvard School of Public Health is releasing a national poll that focuses on Americans' views and concerns about the potential for a more severe outbreak of Influenza A (H1N1) in the fall or winter. The polling was done June 22-28, 2009.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.